Is the plot starting to thicken?, page-3

Apparently...where it is leading to re Asia/Malaysia cannabis for medical purposes is the question but.
10 shares to the cent is around 20 time less than what I bailed out at...snitched a few more at .001 cent just in case. Another 6 or 1 months if Asia follows the lead being set could be somewhat lucrative IMHO.

MJ Life Sciences has a convertible note over Caziwell Inc. The note can be converted into 49.99% of Caziwell Inc. CHP owns 50% of MJ Life Science.

MJ Life Science board of directors is Dr Stewart Washer, Tim Slate (both on ZLD board), Dykes and Dunlop. Former directors Harry Karelis and Jason Peterson (also ZLD Board members).

The shareholders of MJ Life Science are CHP 50% and the other parties listed above (ZLD directors and their mates).

Plus...

Note 21 of the ASX:ZLD 2018 annual report:

1. RELATED PARTY INFORMATION
   
   Transactions between related parties are on commercial terms and conditions, no more favourable than those available to other parties unless otherwise stated.
   
   Transactions with director related entities: Caziwell Inc, a company of which Ms Mara Gordon is a Director, entered into a licence agreement with the Company, including Aunt Zelda’s Inc (Caziwell Licence Agreement) pursuant to which Caziwell agreed to licence patient data concerning the medicinal properties of cannabis and cannabis infused products, including formulations and protocols (Existing Data), to Zelda for use in pre-clinical research and human clinical trials and related activities. The material terms of the Caziwell Licence Agreement are set out in Note 24.

Note 24 of the ASX:ZLD 2018 annual report:

1. CONTINGENT LIABILITIES
   
   Caziwell Licence Agreement On 21 March 2017, Zelda entered into a licence agreement with Caziwell Inc (Caziwell), including Aunt Zelda’s Inc (Caziwell Licence Agreement) pursuant to which Caziwell agreed to licence patient data concerning the medicinal properties of cannabis and cannabis infused products, including formulations and protocols (Existing Data), to Zelda for use in pre-clinical research and human clinical trials and related activities.
   
   The material terms of the Caziwell Licence Agreement are as follows: a. Payment of a royalty to Caziwell of 5% of net sales by Zelda (commencing on the first day that a product is sold, transferred, rented, leased or distributed by or Zelda) for products in the autism, eczema, breast and brain cancer fields. b. A one-off milestone fee of $250,000 payable within 7 days of the first dosage by a participant in a Clinical Trial for breast or brain cancer. c. Zelda may grant sub-licences to the Existing Data and any data generated as a result of the research and clinical trials undertaken by Zelda to third parties for the duration of the Licence. In consideration, Zelda is required to pay Caziwell a sub-licence royalty of 10% of the licence fees and payments, including milestone fees, made by sub-licensees to Zelda in the above fields.
   
   Other than disclosed above, as at the 30 June 2018 the Company did not have any contingent liabilities.

LATEST DEAL SIGNED BY CAZIWELL INC.

THE OIL PLANT INC.

Caziwell Inc (Aunt Zelda's) - recently licenced The Oil Plant the rights to operate in the recreational sector. The Oil Plant just announced this funding deal.
https://www.newswire.ca/news-releases/**riellas-kitchen-secures-foothold-in-california-cannabis-market-with-acquisition-of-the-oil-plant-and-associated-cannabis-licences-693134061.html